At 8.0% CAGR, North America Pharmacokinetics Services Market is Projected to be Worth US$ 692.77 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the North America pharmacokinetics services market was valued at US$ 375.36 million in 2023 and is expected to reach US$ 692.77 million by 2031, registering a CAGR of 8.0% from 2023 to 2031. Rising prevalence of chronic and infectious diseases and expanding range of application of pharmacokinetic studies are among the critical factors attributed to drive the North America pharmacokinetics services market growth.

The growing prevalence of chronic diseases such as diabetes, cancer, and autoimmune diseases has been a prime enabler of drug development efforts across the world. According to the World Health Organization's (WHO) 2024 data, ~422 million in the world suffer from diabetes, and these cases are mostly found in middle and low-income countries, causing approximately 1.5 million deaths every year. Pharmaceutical companies are at the forefront of developing drugs to treat various diseases. Pharmacokinetic studies are essential for understanding how these drugs behave in a patient's body by analyzing the process of absorption, distribution, metabolization, and elimination (ADME) within the human body. The absorption of a drug into systemic circulation affects the speed and concentration at which a drug may reach the site of action, e.g., plasma. Drug distribution pattern throughout the body varies based on its biochemical properties and body physiology. Metabolism involves the processing of the drug by the body into subsequent compounds. This step is instrumental in converting the drug into water-soluble substances to render them suitable for renal clearance. Metabolism is also important for the conversion of prodrugs, such as codeine, into active metabolites. Excretion of drugs from the body is mainly governed by kidneys; however, in several cases, drugs may be excreted via the lungs, skin, or gastrointestinal tract. ADME dynamics define the bioavailability of drugs in the body, and the maintenance doses of drugs are calculated based on their clearance times (desired plasma concentration divided by bioavailability). Understanding of clearance allows practitioners to calculate appropriate dosing rates.

Pharmacokinetic studies focus on optimizing drug dose regimens in study subjects to understand the efficacy and safety of a drug. These studies are essential for ensuring the safety of drugs that are developed for long-term treatments, which helps evaluate the suitability and stability of drug formulations in chronic disease management. Hence, the rising burden of chronic and infectious diseases underlines the importance of pharmacokinetic studies to develop safe and effective personalized treatments.

On the contrary, limited reach of pharmacokinetics service providers in emerging countries hamper the growth of North America pharmacokinetics services market.

Based on drug type, the North America pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held 50.4% market share in 2023, amassing US$ 189.03 million. It is projected to garner US$ 363.90 million by 2031 to register 8.5% CAGR during 2023-2031.

In terms of service type, the North America pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held 35.3% share of North America pharmacokinetics services market in 2023, amassing US$ 132.34 million. It is anticipated to garner US$ 269.59 million by 2031 to expand at 9.3% CAGR during 2023-2031.

By therapeutic application, the North America pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held 22.2% market share in 2023, amassing US$ 83.20 million. It is projected to garner US$ 170.90 million by 2031 to register 9.4% CAGR during 2023-2031.

By end user, the North America pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held 43.3% market share in 2023, amassing US$ 162.42 million. It is projected to garner US$ 316.30 million by 2031 to register 8.7% CAGR during 2023-2031.

By country, the North America pharmacokinetics services market is segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 80.5% share of North America pharmacokinetics services market in 2023. It was assessed at US$ 302.22 million in 2023 and is likely to hit US$ 566.34 million by 2031, registering a CAGR of 8.2% during 2023-2031.

Key players operating in the North America pharmacokinetics services market are Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA; among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com